To evaluate tenofovir-related nephropathy, we quantified calculated glomerular filtration rates (GFR) and renal tubular function in 46 tenofovir-treated patients and 25 without tenofovir. We also analysed patients who stopped tenofovir for drug-related nephrotoxicity at our clinic. Tenofovir use combined with non-nucleoside reverse transcriptase inhibitors, but not with protease inhibitors, resulted in a significant increase in calculated GFR. Tenofovir use was associated with significantly lower phosphatemia and a marginally increased fractional excretion of uric acid, but no other signs of tubulopathy.
aDivision of Infectious Diseases, University Hospital, Berne, Switzerland
bDepartment of Nephrology and Hypertension, University Hospital, Berne, Switzerland.
Received 27 September, 2006
Revised 6 March, 2007
Accepted 16 March, 2007